12% Convertible Note Sample Contracts

12% Convertible Note (February 6th, 2015)

This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

Rich Pharmaceuticals, Inc. – Contract (November 14th, 2014)

NEITHER THIS NOTE NOR THE SECURITIES THAT MAY BE ISSUED BY THE BORROWER UPON CONVERSION HEREOF (COLLECTIVELY, THE "SECURITIES") HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THE SECURITIES NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE 1933 ACT, OR APPLICABLE STATE SECURITIES LAWS; OR (II) IN THE ABSENCE OF AN OPINION OF COUNSEL, IN A FORM ACCEPTABLE TO THE ISSUER, THAT REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT OR; (III) UNLESS SOLD, TRANSFERRED OR ASSIGNED PURSUANT TO RULE 144 UNDER THE 1933 ACT.

Red Giant Entertainment – Contract (August 1st, 2014)

Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES THAT MAY BE ISSUED BY THE BORROWER UPON CONVERSION HEREOF (COLLECTIVELY, THE "SECURITIES") HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THE SECURITIES NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (i) IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE 1933 ACT, OR APPLICABLE STATE SECURITIES LAWS; OR (ii) IN THE ABSENCE OF AN OPINION OF COUNSEL, IN A FORM ACCEPTABLE TO THE ISSUER, THAT REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT OR; (iii) UNLESS SOLD, TRANSFERRED OR ASSIGNED PURSUANT TO RULE 144 UNDER THE 1933 ACT. 12% CONVERTIBLE NOTE Maturity date of January 25, 2015 $100,000 July 25, 2014 (the "Issuance Date") FOR VALUE RECEIVED, Red Giant Entertainment, Inc., a N

Red Giant Entertainment – Contract (July 11th, 2014)

Exhibit 4.5 NEITHER THIS NOTE NOR THE SECURITIES THAT MAY BE ISSUED BY THE BORROWER UPON CONVERSION HEREOF (COLLECTIVELY, THE "SECURITIES") HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THE SECURITIES NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (i) IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE 1933 ACT, OR APPLICABLE STATE SECURITIES LAWS; OR (ii) IN THE ABSENCE OF AN OPINION OF COUNSEL, IN A FORM ACCEPTABLE TO THE ISSUER, THAT REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT OR; (iii) UNLESS SOLD, TRANSFERRED OR ASSIGNED PURSUANT TO RULE 144 UNDER THE 1933 ACT. 12% CONVERTIBLE NOTE Maturity date of December 10, 2014 $50,000.00 June 10, 2014 (the "Issuance Date") FOR VALUE

12% Convertible Note (May 29th, 2012)

THIS NOTE (this "Note") is one of a series of duly authorized and validly issued 12% Convertible Notes (the "Notes") of AtheroNova Inc., a Delaware corporation (the "Company"), having its principal place of business at 2301 Dupont Drive, Suite 525, Irvine, CA 92612.

Sigma Labs, Inc. – B6 Sigma, Inc. 12% Convertible Note (January 18th, 2011)

This Note is unsecured and is subject to conversion into shares of common stock in the Issuer's March 2010 Private Offering (The "Private Offering") on or before the closing of the Reorganization (as such term is defined in the Issuer's March 2010 Private Offering Memorandum [the "Memorandum"]) as set forth in Section 3 hereof. This Note, and all representations, warranties, covenants and agreements contained in herein, shall be binding upon Issuer and its successors and assigns.

Sigma Labs, Inc. – B6 Sigma, Inc. 12% Convertible Note (December 20th, 2010)

This Note is unsecured and is subject to conversion into shares of common stock in the Issuer's March 2010 Private Offering (The "Private Offering") on or before the closing of the Reorganization (as such term is defined in the Issuer's March 2010 Private Offering Memorandum [the "Memorandum"]) as set forth in Section 3 hereof. This Note, and all representations, warranties, covenants and agreements contained in herein, shall be binding upon Issuer and its successors and assigns.

Sigma Labs, Inc. – B6 Sigma, Inc. 12% Convertible Note (November 12th, 2010)

This Note is unsecured and is subject to conversion into shares of common stock in the Issuer's March 2010 Private Offering (The "Private Offering") on or before the closing of the Reorganization (as such term is defined in the Issuer's March 2010 Private Offering Memorandum [the "Memorandum"]) as set forth in Section 3 hereof. This Note, and all representations, warranties, covenants and agreements contained in herein, shall be binding upon Issuer and its successors and assigns.